IGC Pharma reports 50% patient enrollment milestone in Phase 2 CALMA trial

IGC Pharma (IGC) reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer’s disease. This milestone marks a significant step in advancing IGC-AD1, the Company’s proprietary formulation that combines low concentrations of delta-9 tetrahydrocannabinol a naturally derived cannabinoid, with another active pharmaceutical ingredient. Preclinical and clinical evidence suggest that IGC-AD1 has a multi-modal mechanism of action, reducing agitation while also demonstrating potential disease-modifying effects through activity against beta-amyloid plaques, tau tangles and diminished mitochondrial functioning.